SAN DIEGO – DermTech, Inc. (NASDAQ: DMTK) (‘DermTech’ or the ‘Company’), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that the DermTech Melanoma Test (DMT) has tested more than 200,000 suspicious pigmented lesions. The DMT uses non-invasive Smart Stickers to test for select genomic…Read More
DERMTECH SURPASSES 200000 CUMULATIVE BILLABLE SAMPLES FOR THE DERMTECH MELANOMA TEST MarketScreener
